Clinigen Launches Japanese Business to Strengthen Asian Presence
18 October 2016 - 10:00PM
Business Wire
Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or ‘the Group’), the
global pharmaceuticals and services group, has launched its
Japanese business with the opening of an office in Tokyo, Japan.
The establishment of Clinigen K.K. further expands the Group’s
presence in Asia, following Clinigen’s acquisition of Link
Healthcare in 2015. Alongside the launch, Clinigen K.K. will
transfer the Marketing Authorisation for its lead Specialty
Pharmaceutical (SP) product Foscavir® (foscarnet sodium) back from
Nobel Pharma on 1 November 2016. Nobel Pharma has been the
distribution partner for Foscavir in Japan since 2011.
Foscavir is indicated to treat cytomegalovirus (CMV) retinitis
in patients with acquired immunodeficiency syndrome (AIDS) or
Cytomegalovirus viremia and cytomegalovirus disease in
hematopoietic stem cell transplant (HSCT) patients. Japan was the
first market where Clinigen successfully achieved a new license
extension for HSCT patients in 2011.
Japan remains an important market for Foscavir with more than
2,000 patients treated annually. Clinigen will assume full
marketing and distribution responsibility for Foscavir from
November, to supply the product to healthcare professionals and
patients across Japan.
Clinigen K.K. is a significant milestone for the Group in
expanding its global footprint as Japan is the second largest
pharmaceutical market globally. The Japanese business will allow
the Group to supply and distribute both licensed and unlicensed
medicines in the country, providing additional infrastructure to
support Clinigen's mission to deliver the right medicine to the
right patient at the right time. Clinigen employs over 500 people
globally, across 11 locations. The opening of the Japanese office
further expands its international supply chain and operational
network.
Shaun Chilton, Chief Executive Officer, said:
“We are focused on building our market leadership positions by
expanding in key geographic regions to drive sustained organic
growth and better address unmet patient needs for access to
critical medicines. The opening of our Japanese business helps
support our goals and will enable us to effectively serve the
Japanese market by supplying our own products, beginning with
Foscavir. At a time when many pharmaceutical and biotechnology
companies are looking for specialist partners to work with them in
Asia, the opening of our Japanese office gives us more
opportunities to provide customers with our global expertise
combined with local knowledge.”
About Foscavir® (foscarnet sodium)
Foscavir® is licensed for the treatment of cytomegalovirus (CMV)
retinitis in HIV patients, and acyclovir-resistant
mucocutaneous herpes simplex virus (HSV) infections in
immunocompromised patients.
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time and is focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market
leader in the management and supply of commercial medicines for
clinical trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access
programs for innovative new medicines. Idis Global Access
and Link Healthcare work directly with healthcare
professionals to enable compliant access to unlicensed medicines on
a global basis and niche essential licensed and generic medicines
across Australasia, Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global
rights, revitalises and markets its own portfolio of niche hospital
medicines.
For more information, please visit www.clinigengroup.com
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161018005746/en/
Clinigen Group plcShaun Chilton, Chief Executive
OfficerMartin Abell, Chief Financial Officer+44 (0) 1283
495010orNumis Securities LimitedMichael Meade / Freddie
Barnfield (Nominated Adviser)James Black / Tom Ballard (Corporate
Broking)+44 (0) 20 7260 1000orPeel Hunt LLP - Joint
BrokerJames Steel / Dr Christopher Golden+44 (0) 20 7418
8900orInstinctif PartnersMelanie Toyne-Sewell / Jen Lewis /
Jayne Crook+44 (0) 20 7457 2020clinigen@instinctif.comorClinigen
K.K.Masahiko Iwasaki, General ManagerTel:
+81-(0)3-6869-0663Fax: +81-(0)3-6869-0660
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024